Cargando…
LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
Although most pediatric LGG (PLGG) have excellent long-term survival, there is a subset of cases that disseminate throughout the neuraxis (DLGG) that have very poor outcomes. The reason for this aggressive behavior is unknown but we hypothesize that distinct and specific biological mechanisms underl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260182/ http://dx.doi.org/10.1093/neuonc/noad073.222 |
_version_ | 1785057807761932288 |
---|---|
author | Levine, Adrian Li, Cyril Haizel-Cobbina, Joseline Nobre, Liana Bennett, Julie Dewan, Michael Tabori, Uri Hawkins, Cynthia |
author_facet | Levine, Adrian Li, Cyril Haizel-Cobbina, Joseline Nobre, Liana Bennett, Julie Dewan, Michael Tabori, Uri Hawkins, Cynthia |
author_sort | Levine, Adrian |
collection | PubMed |
description | Although most pediatric LGG (PLGG) have excellent long-term survival, there is a subset of cases that disseminate throughout the neuraxis (DLGG) that have very poor outcomes. The reason for this aggressive behavior is unknown but we hypothesize that distinct and specific biological mechanisms underlie the metastatic ability. The methylation-based class of diffuse leptomeningeal glioneuronal tumor (DLGNT) is characterized by MAPK pathway activating fusions with chromosome 1p loss, 19q loss, and/or 1q gain. However, it is unknown what proportion of DLGG match the DLGNT group, and which other methylations classes are at risk of metastasis. To improve our understanding of this rare patient population, we created an international DLGG consortium. Data from the first 68 cases shows a broad age distribution and no sex predilection. As expected, DLGG has much worse prognosis than the overall PLGG population. Virtually all DLGG progress at 5 years, compared to a quarter of other PLGG, and DLGG are 5-times more likely to die at 10 years. We observe three patterns of dissemination – 35% present with a localized mass and have secondary dissemination, 50% with disseminated tumor and a clear dominant mass, and 15% with disseminated disease without a dominant mass. In 47 patients with molecular testing, BRAF fusions accounted for 64% of driver alterations. Additional alterations were identified less frequently, including BRAF V600E (9%), FGFR1 alterations (9%), and KRAS mutations (4%). In 25 patients with methylation profiling, 10 (40%) successfully classified with a calibrated score above 0.8, illustrating that many cases do not fit a defined methylation group. The most common methylation classification was pilocytic astrocytoma (5 patients), and surprisingly only two patients classified as DLGNT. In sum this study illustrates the variable clinical behaviour associated with metastasis in PLGG and expands the range of molecular driver alterations, including ones previously unreported in DLGNT. |
format | Online Article Text |
id | pubmed-10260182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102601822023-06-13 LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA Levine, Adrian Li, Cyril Haizel-Cobbina, Joseline Nobre, Liana Bennett, Julie Dewan, Michael Tabori, Uri Hawkins, Cynthia Neuro Oncol Final Category: Low Grade Gliomas - LGG Although most pediatric LGG (PLGG) have excellent long-term survival, there is a subset of cases that disseminate throughout the neuraxis (DLGG) that have very poor outcomes. The reason for this aggressive behavior is unknown but we hypothesize that distinct and specific biological mechanisms underlie the metastatic ability. The methylation-based class of diffuse leptomeningeal glioneuronal tumor (DLGNT) is characterized by MAPK pathway activating fusions with chromosome 1p loss, 19q loss, and/or 1q gain. However, it is unknown what proportion of DLGG match the DLGNT group, and which other methylations classes are at risk of metastasis. To improve our understanding of this rare patient population, we created an international DLGG consortium. Data from the first 68 cases shows a broad age distribution and no sex predilection. As expected, DLGG has much worse prognosis than the overall PLGG population. Virtually all DLGG progress at 5 years, compared to a quarter of other PLGG, and DLGG are 5-times more likely to die at 10 years. We observe three patterns of dissemination – 35% present with a localized mass and have secondary dissemination, 50% with disseminated tumor and a clear dominant mass, and 15% with disseminated disease without a dominant mass. In 47 patients with molecular testing, BRAF fusions accounted for 64% of driver alterations. Additional alterations were identified less frequently, including BRAF V600E (9%), FGFR1 alterations (9%), and KRAS mutations (4%). In 25 patients with methylation profiling, 10 (40%) successfully classified with a calibrated score above 0.8, illustrating that many cases do not fit a defined methylation group. The most common methylation classification was pilocytic astrocytoma (5 patients), and surprisingly only two patients classified as DLGNT. In sum this study illustrates the variable clinical behaviour associated with metastasis in PLGG and expands the range of molecular driver alterations, including ones previously unreported in DLGNT. Oxford University Press 2023-06-12 /pmc/articles/PMC10260182/ http://dx.doi.org/10.1093/neuonc/noad073.222 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Final Category: Low Grade Gliomas - LGG Levine, Adrian Li, Cyril Haizel-Cobbina, Joseline Nobre, Liana Bennett, Julie Dewan, Michael Tabori, Uri Hawkins, Cynthia LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA |
title | LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA |
title_full | LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA |
title_fullStr | LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA |
title_full_unstemmed | LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA |
title_short | LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA |
title_sort | lgg-12. clinical and molecular features of disseminated pediatric low-grade glioma |
topic | Final Category: Low Grade Gliomas - LGG |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260182/ http://dx.doi.org/10.1093/neuonc/noad073.222 |
work_keys_str_mv | AT levineadrian lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma AT licyril lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma AT haizelcobbinajoseline lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma AT nobreliana lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma AT bennettjulie lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma AT dewanmichael lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma AT taboriuri lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma AT hawkinscynthia lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma |